Michael Bishop to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Michael Bishop has written about Leukemia, Myeloid, Acute.
Connection Strength
1.895
-
Current Status of CAR T Cell Therapy for Leukemias. Curr Treat Options Oncol. 2021 06 07; 22(7):62.
Score: 0.460
-
Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies. Curr Opin Hematol. 2013 Mar; 20(2):115-22.
Score: 0.260
-
Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S62-73.
Score: 0.239
-
Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. J Clin Oncol. 2000 Jun; 18(11):2269-72.
Score: 0.107
-
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020 11; 55(11):2204-2206.
Score: 0.107
-
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.
Score: 0.091
-
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
Score: 0.091
-
Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J Hematother. 1997 Oct; 6(5):441-6.
Score: 0.089
-
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol. 1996 Apr; 14(4):1320-6.
Score: 0.080
-
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34.
Score: 0.076
-
Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion. Chin Med J (Engl). 2013 Nov; 126(22):4380-8.
Score: 0.068
-
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012 Feb; 47(2):203-11.
Score: 0.057
-
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2006 Feb; 12(2):204-16.
Score: 0.040
-
Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2002 Apr; 29(8):709-10.
Score: 0.030
-
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma. 2000 Mar; 37(1-2):65-70.
Score: 0.026
-
Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment. J Toxicol Clin Toxicol. 2000; 38(4):383-7.
Score: 0.026
-
Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994 Dec; 12(12):2527-34.
Score: 0.018
-
Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev. 1993; 3(4):383-90.
Score: 0.016
-
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503.
Score: 0.014